PharmaMar has requested the process of re-examination for AplidinĀ® from the EMA
(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for AplidinĀ® (plitidepsin) for the indication of relapsed...

